XTANDI (Astellas Pharma Australia Pty Ltd)
Product name
XTANDI
Date registered
Evaluation commenced
Decision date
Approval time
173 working days (255)
Active ingredients
enzalutamide
Registration type
EOI
Indication
XTANDI (soft capsules) is now also indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.